When her lymphoma returned, Diann Jackson turned to an innovative immunotherapy that University of Mississippi Medical Center officials say offers new hope for patients with aggressive cancers.
The University of Mississippi Medical Center said the treatment is part of expanding access to precision care at the Jackson academic medical center. UMMC said BiTE immunotherapy is becoming an important option for patients with fast-growing cancers.
BiTE, short for bispecific T-cell engager, is a form of immunotherapy that directs a patient’s T cells to recognize and attack cancer cells. Researchers and clinicians have increasingly used immunotherapies in recent years to treat certain blood cancers and solid tumors, particularly when standard treatments fail or disease returns.
The move by Jackson to pursue BiTE therapy illustrates broader efforts by hospitals and cancer centers to broaden treatment options for relapsed and aggressive malignancies. We will provide more information as it becomes available.
